Cargando…
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for efavirenz pharmacokinetics, auto-induction, and im...
Autores principales: | Mugusi, Sabina, Habtewold, Abiy, Ngaimisi, Eliford, Amogne, Wondwossen, Yimer, Getnet, Minzi, Omary, Makonnen, Eyasu, Sudfeld, Christopher, Burhenne, Jürgen, Aklillu, Eleni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019112/ https://www.ncbi.nlm.nih.gov/pubmed/32116703 http://dx.doi.org/10.3389/fphar.2020.00026 |
Ejemplares similares
-
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
por: Ngaimisi, Eliford, et al.
Publicado: (2013) -
Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa
por: Machado, Lee R., et al.
Publicado: (2013) -
Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
por: Aklillu, Eleni, et al.
Publicado: (2020) -
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011) -
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
por: Aklillu, Eleni, et al.
Publicado: (2013)